-+ 0.00%
-+ 0.00%
-+ 0.00%

Reported Saturday, Rhythm Pharmaceuticals Reports Statistically Significant BMI Reductions In Children And Adults Across Multiple Doses And Subgroups In TRANSCEND And SIGNAL Trials

Benzinga·07/14/2025 06:51:46
Listen to the news
  • Presentations highlight clinically meaningful reductions in BMI in patients with acquired hypothalamic obesity –
  • - Full data from Phase 3 TRANSCEND study underscore potential efficacy of setmelanotide, including with prior use or concomitant use of GLP